

MedIntel – Agentic AI- Based Clinical Trial Recommender System

WHEN STANDARD MEDICINE STOPS, INTELLIGENT SEARCH
BEGINS.



INTRO


The Challenge in Modern Healthcare



PROBLEM


- Patients with rare or terminal diseases often run out of standard treatments.
- Thousands of clinical trials exist — but hard to find the right one.
- Doctors don't have time or tools to manually match eligibility.

SOLUTION



An Agentic AI that Finds Hope in Research

- Reads patient data automatically.
- Searches global clinical trials.
- Uses AI reasoning to calculate match score (%).
- Notifies doctor instantly via email.
- Continuously updates google sheet as new data arrives.






Why This Matters

- Saves research time
- Uncovers hidden treatment options
- Real-time notifications
- Moves toward personalized medicine

How MedIntel Works (n8n Agentic Flow)





Fetch patient details
from Google Sheets



Extract trials from
ClinicalTrials.gov API



Summarize each trial
(OpenAI node)




Compare with patient profile
(LLM reasoning)



Generate match score
(0-100)



Send doctor alert
for strong matches



Fetch patient details
from Google Sheets

Inside the Automation

An automated AI pipeline that reads patient data, analyzes global trials, and instantly informs doctors about best-matching research opportunities.

Automated Doctor Alert

MedIntel delivers
concise trial
recommendations
with scores and
summaries — no
manual searching
needed.

Placebo-Controlled, Parallel-Group Study to Investigate the Clinical Efficacy and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects Inbox x



alluruishitha@gmail.com
to me ▾

Fri 31 Oct, 23:47 (11 hours ago)



New Trial Match (75%)

Patient: (ID:P003)

Condition:Diabetes

Biomarkers: bio

ECOG:0

Trial: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical Efficacy and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects

Phase: PHASE3

NCT ID: NCT01103284

Link: clinicaltrials.gov/study/NCT01103284

Locations: Los Gatos, United States; Sutter Gold Medical Foundation, Modesto, United States; San Diego Clinical Trials, San Diego, United States; University of Colorado Hospital - Anschutz Outpatient Pavilion, Aurora, United States; Creekside Endocrine Associates, Inc., Denver, United States

Why this match: The patient's condition and general parameters are a plausible fit for the trial, but specific details are missing to confirm a strong match.

MedIntel delivers
concise trial
recommendations
with scores and
summaries — no
manual searching
needed.

MedIntel_Patients ☆ 📁 ☁️
File Edit View Insert Format Data Tools Extensions Help Ask Gemini

🔍 ↶ ↷ 🖨 🗑 100% ▾ £ % .0 .00 123 Default... ▾ - 10 + B I 🔃 A 🎯 🏠 📊 ▾ ≡ ▾ ↓ ▾ ⇅ ▾ ⚙ ▾ ^

	A	B	C	D	E	F	G	H	I	J	K	L
1	PatientID	Name	Condition	Stage	Biomarkers	TrialTitle	Phase	MatchScore	Summary	NCTUrl	Locations	DoctorName
2	P003	Sneha Patel	Diabetes	Type II	bio	Efficacy and Safe	PHASE3	75	The trial is a plausible match for the patient, with several key criteria			
3	P001	Riya Sharma	Breast Cancer	Stage II	HER2+	Doxorubicin Hyd	PHASE2	75	The trial appears to be a plausible match for the patient, with several			
4	P003	Sneha Patel	Diabetes	Type II	bio	Role of Endothel		75	The trial appears to be a plausible option for the patient given the pre			
5												
6												
7												
8												
9												
10												
11												
12												
13												
14												
15												
16												
17												

+ ≡ Patients ▾ MatchedTrials ▾ <

Tech Stack & Tools

Category	Tools
Workflow Automation	n8n (Docker)
AI Model	OpenAI / OpenRouter LLM
Data Source	ClinicalTrials.gov API
Notification	Gmail SMTP
Storage	Google Sheets




Expanding MedIntel

- 🏥 Integrate with hospital EMR systems
- 💡 Add clinical trial recommendation dashboard
- 📊 Build patient-trial analytics reports
- 📱 Deploy WhatsApp bot for doctor queries
- 🌐 Support multi-language trial summaries






**When knowledge
meets automation,
new cures become
visible.**

MEDINTEL BRINGS PRECISION AI TO LIFE-SAVING
RESEARCH CONNECTIONS

